$ORIC

Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC recently reduced its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 14.2% in the third quarter, selling 180,957 shares and retaining over 1 million shares valued at approximately $13.17 million. This move comes as company insiders have also been net sellers, with CEO Jacob Chacko and another insider selling shares totaling over $1.20 million in the past three months. Despite insider selling, analysts maintain a "Moderate Buy" consensus and a price target of $20.20 for ORIC, which is currently trading around $11.90.

Original reporting
MarketBeat · MarketBeat
Published Mar 15, 2026, 7:51 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 15, 2026, 9:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC — source image
Decision brief

The 30-second read

$ORICNeutralMed
01

Why it matters

While insider and institutional selling can signal caution, the overall analyst sentiment remains moderately bullish, with a price target of $20.20 compared to the current trading price around $11.90.

02

Market read

The insider activity and stake reduction are noteworthy but do not definitively predict a trend; traders should watch for further insider or institutional moves.

03

What to watch

Potential upcoming catalysts such as clinical trial results or partnership announcements could offset insider activity concerns

Timing: short to medium term

Background

ArrowMark Colorado Holdings LLC reduced its stake in ORIC by 14.2% in Q3, selling approximately 180,957 shares, while insiders including the CEO sold over $1.2 million worth of shares in the past three months.

Company-level read

Ticker impact

$ORICNeutralMedium confidence
Context

Recent insider activity and institutional stake reduction

Expected impact

Potential short-term price decline followed by stabilization

Evidence & confidence

While insider selling and stake reduction may indicate caution, analyst ratings and price targets support a moderate bullish outlook. Lack of significant negative news limits downside risk.

Market effects

Possible minor impact on biotech and life sciences sector sentiment

Limited regional impact due to company-specific news

Low, as news is company-specific and insider activity

Counterpoint

Insider selling may be routine and not indicative of future performance; the company’s fundamentals and analyst support suggest long-term growth potential

Key entities

  • ArrowMark Colorado Holdings LLC

    A hedge fund that reduced its stake in ORIC.

  • Jacob Chacko

    Insider who sold shares totaling over $600,000 in recent months.

Related articles

$ORICMed

Oric Pharmaceuticals, Inc. (ORIC): Results of Operations and Financial Condition

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 oric-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.